Data from an epidemiologic analysis of
|
|
- Alberta Blake
- 5 years ago
- Views:
Transcription
1 CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated with a marked reduction in the occurrence of complications in patients with type 2 diabetes, A 1c is not well controlled in most of these patients in the United States. Follow-up data from the National Health and Nutrition Examination Survey showed that only 37% of people with type 2 diabetes achieved an A 1c of less than 7% in The frequent occurrence of suboptimal A 1c control with present therapies has led to investigations of possible approaches to increase glucagon-like peptide- 1 (GLP-1) receptor activation, one method of improving glycemia in patients with type 2 diabetes. These approaches include agents that are analogs of GLP-1; oral dipeptidyl peptidase-iv (DPP-IV) inhibitors that act to prolong the activity of endogenous GLP-1; and a synthetic version of the naturally occurring peptide exendin-4 (exenatide), which exhibits GLP-1 receptor binding in vitro equivalent to that of GLP-1. Liraglutide (NN2211), a long-acting, acylated GLP-1 analog currently in regulatory investigational trials, has exhibited significant reduction of A 1c versus placebo at certain dosages. CJC-1131, another GLP-1 analog, also has been associated with improvement in A 1c compared to placebo. Vildagliptin (NVP- LAF237), a long-acting DPP-IV inhibitor, has been associated with significant decreases in A 1c from baseline compared to placebo; a glycemic Based on a presentation given by Dr Blonde at a satellite symposium held during the American Diabetes Association s 65th Annual Scientific Sessions, San Diego, California. Director, Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Associate Residency Program Director, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana. Address correspondence to: Lawrence Blonde, MD, FACP, FACE, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA lblonde@ochsner.org. benefit maintained out to 52 weeks in an openlabel extension trial. Exenatide is a 39-amino acid peptide structurally identical to native exendin-4 and resistant to inactivation by DPP-IV. In clinical trials involving patients with type 2 diabetes previously treated with metformin, a sulfonylurea, or the combination of metformin and a sulfonylurea, addition of exenatide produced significant reductions in A 1c, weight loss, and improvement in β-cell function. This review summarizes clinical trial data on efficacy, safety, tolerability, and other effects for each of these incretin-related agents. (Adv Stud Med. 2005;5(10E):S1074-S1078) Data from an epidemiologic analysis of the United Kingdom Prospective Diabetes Study showed that in people with type 2 diabetes, reduction of A 1c (also known as glycated hemoglobin) was associated with a marked decrease in the occurrence of micro- and macrovascular complications. 1 Yet despite this information, A 1c is not well controlled in most people with type 2 diabetes in the United States. Data from the National Health and Nutrition Examination Survey III in 1994 showed that only 44% of people with type 2 diabestes achieved an A 1c of less than 7%. 2 In the year 2000, this number actually decreased to 37%. 3 Recently at a meeting of the American Association of Clinical Endocrinologists, a report was issued on the state of diabetes health showing that in a study of Americans in 39 states, 66% of individuals with type 2 diabetes were above the American College of Endocrinology (ACE) goal for glycemic control of 6.5% or less. 4 In every state studied, more than 50% of the population studied was S1074 Vol. 5 (10E) December 2005
2 above the ACE goal. Present therapies are associated with a number of challenges that contribute to suboptimal control. In people with type 2 diabetes, these challenges include difficulty in attenuating the postprandial rise in glycemia, the association of most therapies with a progressive loss of glycemic control over time that appears related to a progressive decline in β- cell function, 5 and the association of most antihyperglycemic treatments with weight gain. Glucagon-like peptide-1 (GLP-1) has a number of antihyperglycemic actions, including enhancement of glucose-dependent insulin secretion, inhibition of postprandial glucagon secretion, slowing of gastric emptying, and enhancement of satiety. GLP-1 levels are decreased in people with type 2 diabetes, and infusing GLP-1 improves glycemia in patients with type 2 diabetes. However, because GLP-1 is rapidly inactivated after administration, continuous infusion, which is not a desirable option, would be required for GLP-1 to serve as a therapeutic agent. There has been active investigation of other possible approaches to increasing GLP-1 receptor activation, such as analogs of GLP-1, a synthetic version (exenatide) of the naturally occurring peptide exendin-4, and oral dipeptidyl peptidase-iv (DPP-IV) inhibitors. Trial results to date with these agents taken as a group indicate they have antihyperglycemic efficacy with mild to moderate side effects and the absence of weight gain. Exenatide, recently approved by the US Food and Drug Administration (FDA), actually has been associated with significant weight loss. Furthermore, GLP-1 related treatment may offer the potential of preserving or enhancing β-cell function and/or β-cell mass. This paper discusses certain aspects of the clinical trial results with these GLP-1 related therapies. GLUCAGON-LIKE PEPTIDE-1 ANALOGS Liraglutide (NN2211) is a long-acting, acylated GLP-1 analog currently in regulatory investigational trials. In one 12-week, double-blind, randomized, parallel-group, placebo-controlled trial of liraglutide involving 193 outpatients with type 2 diabetes, A 1c decreased in all but the lowest liraglutide dosage group. 6 In the 0.75-mg liraglutide group, A 1c decreased by 0.75 percentage points compared to placebo (P <.0001). In this study, liraglutide was associated with a very low incidence of hypoglycemia and no consistent effect on body weight. At certain doses, slight weight loss was seen, whereas at other doses there was no change in weight. The incidence of nausea seemed to increase with increasing doses of liraglutide. Other observed gastrointestinal events (eg, diarrhea, vomiting, and constipation) in this study were mild and transient, generally resolving in 1 to 3 days. A 12-week, randomized, double-blind, placebo-controlled phase II clinical study of CJC-1131, another GLP-1 analog, assessed effects of once-daily dosing on glycemic control in patients with type 2 diabetes who were inadequately controlled, despite treatment with metformin alone or in combination with a sulfonylurea. 7 Treatment with CJC-1131 was associated with a mean -1.1% greater A 1c change from baseline (7.93%) than placebo (P <.0001). CJC-1131 treatment also was associated with a mean placebo corrected weight loss of 0.9 kg. Nausea was the only major side effect. DIPEPTIDYL PEPTIDASE-IV INHIBITORS Vildagliptin (NVP LAF237) is a long-acting DPP- IV inhibitor that prolongs the activity of endogenous GLP-1. DPP-IV is a widely expressed enzyme that has postproline and postalanine peptidase activity and, as a result, both inactivates and activates peptides. Its substrates in the gut endocrine system are not solely GLP-1. Others include gastrin-releasing peptide, glucose-dependent insulinotropic peptide, glucagon-like peptide-2, and peptide YY. In a 12-week, placebo-controlled study of vildagliptin in metformin-treated patients with type 2 diabetes, A 1c decreased (-0.6% ± 0.1%) from a mean baseline of 7.7%, whereas A 1c did not change in the placebo group. 8 An open-label extension of this trial demonstrated maintenance of the glycemic benefit out to 52 weeks with vildagliptin, whereas there was further loss of glycemic control in the placebo group. Vildagliptin was associated with a low incidence of hypoglycemia and appeared to be weight neutral (in the 12- week core study, body weight decreased 0.4 ± 0.2 kg in patients receiving vildagliptin plus metformin, whereas body weight in the placebo group decreased by 0.5 ± 0.2 kg; in the extension study weight change [-0.2 kg] was the same in both groups). Tolerability of vildagliptin was comparable with placebo. Another DPP-IV inhibitor, MK-0431, also is entering late-stage clinical development. In 2 doseranging studies, treatment of patients with type 2 diabetes for 12 weeks resulted in placebo-corrected reductions in A 1c of 0.4% to 0.8%. Changes in weight were not observed in the 2 studies. 9,10 Advanced Studies in Medicine S1075
3 EXENATIDE Exenatide (synthetic exendin-4) is a 39-amino acid peptide that is structurally identical to native exendin- 4. GLP-1 receptor binding with exenatide is equivalent to GLP-1. Exenatide is rapidly absorbed after subcutaneous injection, is resistant to inactivation by DPP-IV, is suited for twice-daily injection, and recently received FDA approval for treatment of patients with type 2 diabetes who have not achieved adequate glycemic control, despite treatment with metformin and/or a sulfonylurea. Exenatide has been shown to improve β-cell function and lower glucose. In a study of 12 patients with type 2 diabetes who had previously been treated with diet or oral agents, the injection of exenatide was associated with a marked increase in insulin secretion and a resultant fall in glycemia. 11 But as is characteristic of GLP-1 related compounds, as glucose levels approached the normal range, there was an attenuation of insulin secretion. The glucose-dependent insulin secretion with this agent should reduce the risk for hypoglycemia. In individuals who do not have diabetes, intravenous glucose results in a very rapid first-phase insulin secretion followed by more prolonged, second-phase insulin secretion. Patients with type 2 diabetes receiving intravenous glucose display an attenuation or absence of this first-phase insulin response. Fehse et al studied 13 subjects with type 2 diabetes and compared them to 12 healthy subjects with normal glucose tolerance. 12 Treatment of patients with type 2 diabetes with exenatide increased insulin (P <.005) and C-peptide areas under the curve (P <.005) during the first (0 10 min) and second ( min) phases after intravenous glucose by 2- to 4-fold relative to placebo. Exenatide-treated patients with type 2 diabetes had a secretory pattern similar to healthy subjects, in contrast to patients with type 2 diabetes treated with placebo who had blunted first-phase insulin secretion compared to healthy control subjects. This study thus demonstrated the ability of exenatide to acutely improve β-cell function and restore and enhance the first-phase insulin response of patients with type 2 diabetes. Exenatide versus placebo injected subcutaneously was compared to placebo in patients with type 2 diabetes being treated with diet and/or oral antidiabetic agents. 13 One hundred nine patients were assigned to 1 of 3 exenatide regimens or placebo for 28 days. After 28 days of exenatide treatment, all 3 treatment groups showed significant reductions in serum fructosamine (P.004), A 1c (P.006), and attenuation of the postprandial rise in plasma glucose (P.004) compared to placebo. There was no change in body weight from day 1 to day 28. Three phase III pivotal trials of 30 weeks duration compared exenatide versus placebo in patients with type 2 diabetes who had not achieved glycemic control, despite treatment with metformin, a sulfonyl-urea, or the combination of metformin and a sulfonylurea There were 336 and 377 patients in the first 2 studies respectively, and 733 in the third, with a 2-to-1 randomization in favor of exenatide. Intent-to-treat A 1c results from these trials (Figure 1) in individuals with a baseline A 1c ranging from 8.2% to 8.7% showed an approximate 1% decrease in A 1c compared to placebo in all 3 trials. Weight loss was seen in each of the 3 studies, with a mean weight loss of approximately 2 kg across the studies (Figure 2). The greatest weight loss occurred in the group of patients in whom exenatide was added to metformin. These trials also assessed the percentage of patients achieving A 1c of 7% or below. In the metformin trial, 46% of patients receiving exenatide 10 µg twice daily achieved an A 1c of 7% or below. 14 In the sulfonylurea trial, 41% of patients at the highest dosage of exenatide (10 µg twice daily) achieved an A 1c of 7% or below. 15 In the trial comparing exenatide and placebo in patients not at goal, despite receiving a combination metformin and sulfonylurea therapy individuals who would be expected to have more advanced type 2 diabetes 34% of patients receiving exenatide 10 µg twice daily achieved an A 1c of 7% or below. 16 A 52-week open-label extension of each of the 3 trials also was completed. 17 All patients, irrespective of treatment during the 30-week trial, were initially treated with exenatide 5 µg twice daily for the first 4 weeks of the open-label extension, and then were advanced to 10 µg twice daily. Upon receiving exenatide, patients who previously had been in the placebo cohort had a rapid decrease of A 1c similar to that observed with exenatide treatment in the first 30 weeks. Mean A 1c reductions from baseline were very similar at 82 weeks (at least -1.1%) for all 3 original study treatment groups. For patients receiving 10 µg exenatide twice daily for 82 weeks, 51% achieved an A 1c of 7% or below at 82 weeks. Placebo-treated subjects in the initial trial, upon S1076 Vol. 5 (10E) December 2005
4 receiving exenatide in the extension, showed a significant decrease of weight similar to that observed with exenatide treatment in the first 30 weeks. 17 Mean body weight reductions mediated by exenatide during the first 30 weeks were sustained and appeared to be progressive through 82 weeks with a mean weight loss of approximately 10 lbs compared with baseline. Preliminary 2-year data demonstrate that these effects on glycemic control and weight appear to persist. In the 30-week trial in which metformin-treated patients with type 2 diabetes were randomized to exenatide 5 or 10 µg twice daily or placebo, the reported incidence of hypoglycemia was no greater for exenatide than for placebo-treated subjects. 14 This low incidence of hypoglycemia is what would be anticipated for an agent producing glucose-dependent insulin secretion. When exenatide was added to patients treated with sulfonylurea alone or sulfonylurea plus metformin, an increase in hypoglycemia compared to placebo was observed. However, exenatide subjects also had achieved a significantly lower A 1c, and there were no episodes of serious hypoglycemia and only 1 episode of severe hypoglycemia (requiring the assistance of another person) in these studies. 15 Other adverse events in the 30-week trials that were more frequent in exenatide than in placebo-treated subjects were mostly gastrointestinal in nature. Nausea, the most frequent side effect, was mostly mild to moderate in intensity. Only 3% of exenatide and 1% of placebo-treated patients discontinued the study because of nausea. The incidence of nausea decreased over time. In contrast, as noted earlier in this article, weight loss with exenatide continued to progress over time, and weight loss also was seen in subjects without nausea, indicating that weight loss was not primarily caused by nausea. 18 CONCLUSIONS Glucagon-like peptide-1 appears to be deficient in people with type 2 diabetes, and enhancing GLP-1 receptor activation can improve glycemic control, especially after meals. GLP-1 analogs, DPP-IV inhibitors, and synthetic exendin-4 (exenatide) have been in development, and exenatide has recently received FDA approval. Trial results to date indicate these agents are effective in lowering blood glucose with mild-to-moderate side effects and are not associated with the weight gain seen with most antihyper- Figure 1. Large Phase III Clinical Studies (ITT) A 1c Results A1c, % Figure 2. Weight Changes: Exenatide + Oral Agent Therapy 30-Week, Randomized, Placebo- Controlled Trials A1c, % MET SFU MET + SFU -0.4 MET SFU MET+ SFU n Baseline, % n Baseline, % Placebo BID 5 µg exenatide BID 10 µg exenatide BID A 1C = glycated hemoglobin; BID = twice daily; MET = metformin; SFU = sulfonylurea. P <.05. Adapted with permission from DeFronzo et al 14 ; Buse et al 15 ; and Kendall et al Placebo BID 5 µg exenatide BID 10 µg exenatide BID A 1c = glycated hemoglobin; BID = twice daily; MET = metformin; SFU = sulfonylurea. P <.005. Adapted with permission from DeFronzo et al 14 ; Buse et al 15 ; and Kendall et al. 16 Advanced Studies in Medicine S1077
5 glycemic therapies. Indeed, exenatide therapy is associated with significant weight loss. These agents also may offer the potential to preserve or enhance β-cell function and even β-cell mass. Further studies that attempt to elucidate these potential β-cell effects are eagerly anticipated. REFERENCES 1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281: Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291: American Association of Clinical Endocrinologists. State of diabetes in America. Available at: com/pub/stateofdiabetes/stateofdiabetes.php. Accessed: September 29, U.K. Prospective Diabetes Study 16. Overview of 6 year s therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [published correction appears in Diabetes. 1996;45:1655]. Diabetes. 1995;44: Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27: Ratner RR, Guivarch PH, Dreyfus JF, et al. Effects of DAC- GLP:1 (CJC-1131) on glycemic control and weight over 12 weeks in metformin-treated patients with type 2 diabetes. Presented at: the American Diabetes Association 65th Scientific Sessions; June 10-14, 2005; San Diego, Calif. 8. Ahren B, Somis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27: Chen X, Wu M, Stein P. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes [abstract]. Diabetes. 2005;54:A Herman GA, Hanefeld M, Wu M, et al. Effect of MK- 0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes [abstract]. Diabetes. 2005;54:A Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88: Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocl Metab. 2005;90: Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26: DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28: Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27: Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28: Blonde L, Han J, Mac S, et al. Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes [abstract]. Diabetes. 2005;54: Abstract Number 477-P. 18. Maggs D, Kim D, Holcombe J, et al. Exenatide-induced reductions in A1C and body weight in long-term trials are not explained by gastrointestinal side effects [abstract]. Diabetes. 2005;54:A120. S1078 Vol. 5 (10E) December 2005
Aclearer understanding of incretin biology
THERAPEUTIC STRATEGIES BASED ON GLP-1 PATHWAYS Adriana Costa e Forti, MD, PhD* ABSTRACT Greater understanding of incretin biology has led to the development of new approaches to the treatment of type 2
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationSELECTED ABSTRACTS AND POSTER PRESENTATIONS
SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationThe effective management of type 2
Approximately two thirds of patients with type 2 diabetes mellitus (T2DM) are unable to reach the hemoglobin A 1c target set by the American Diabetes Association ( 7.0%). Therefore, T2DM continues to be
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationThe prevalence of type-2 diabetes is increasing at
Non-insulin injectable therapy The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected it. To reduce the risk of the associated microvascular
More informationTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert
REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationIn this article, the efficacy and limitations of pharmacologic
The Diabetes EDUCATOR 72S The Evidence for Achieving Glycemic Control With Incretin Mimetics Learning Objectives Identify at least 1 benefit and 1 barrier to each of the 6 classes of antihyperglycemic
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationSYSTEMATIC REVIEW. Introduction. X. Xue, 1 Z. Ren, 1 A. Zhang, 2 Q. Yang, 3 W. Zhang, 4 F. Liu 1,4
SYSTEMATIC REVIEW Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationMechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Adv Ther (2013) 30(2):81 101. DOI 10.1007/s12325-013-0009-4 REVIEW Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes Michael Horowitz Christopher K. Rayner Karen L.
More informationGLP-1 Agonists for Diabetes
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationAccording to the Indications and Usage section of the FDA-approved product labeling (PI) 1 :
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Rexner Vargas, Senior Manager, Regulatory Affairs Amylin Pharmaceuticals,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More information(English) Palabras clave: Diabetes. Exenatide. Insulina. Glargina. Insulina isofánica. Análisis costebeneficiot.
Original Research Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Krystal L. EDWARDS,
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationLiraglutide: First Once-Daily Human GLP-1 Analogue
DRUG PROFILE KERALA MEDICAL JOURNAL Liraglutide: First Once-Daily Human GLP-1 Analogue Sreejith N Kumar Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram* ABSTRACT Published
More informationExpanding Treatment Options for Diabetes: GLP-1 Receptor Agonists. Copyright
CLINICAL Viewpoint Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists Advancements in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationCurrent therapies for type 2 diabetes
Reviews/Commentaries/ADA R E V I E W A R T I C L E Statements Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 MATTHEW C. RIDDLE, MD 1 DANIEL J. DRUCKER, MD 2 Current therapies
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
REVIEW Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Nasser Mikhail Endocrinology Division, Olive View-UCLA Medical
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationRESEARCH. What this study adds. What is already known about this subject
RESEARCH Evaluating the Short-Term Cost-Effectiveness of Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States Jakob Langer, MSc; Barnaby Hunt, BSc; and
More informationUse of Exenatide in Patients With Type 2 Diabetes
Feature Article/Hood et al. Use of Exenatide in Patients With Type 2 Diabetes Robert Hood, MD; Virginia Valentine, CNS, BC-ADM, CDE; Susanna Mac, MD, PhD; and William H Polonsky, PhD, CDE Abstract Glucose
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationEfficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Supplement issue Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD Diabetes and Metabolism Translational Medicine
More informationSupplementary Online Content
Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes.
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationPersonalized therapeutics in diabetes
Personalized therapeutics in diabetes Leen M. t Hart Molecular Cell Biology & Molecular Epidemiology Leiden University Medical Center Epidemiology & Biostatistics VU University Medical Center Diabetes
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationPharmacy Drug Class Review. Type 2 Diabetes Mellitus Focus on DPP-4 inhibitors, Glp-1 Analogs, And Amylin Analogs
Pharmacy Drug Class Review November 30, 2009 Disclaimer: Specific agents may have variations Authored By: Kirsten Butterfoss Pharm. D. Candidate 2010; Edited By: Richard J. Kraft, Pharm.D., Type 2 Diabetes
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationDURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Diabetes Care Publish Ahead of Print, published online March 9, 2010 DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks Running Title: Exenatide once weekly,
More informationChapter 5. GLP-1 Based Therapies: Differential Effects on Fasting and Postprandial Glucose
Chapter 5 GLP-1 Based Therapies: Differential Effects on Fasting and Postprandial Glucose Mark Fineman, Brenda Cirincione, David Maggs, Michaela Diamant Diabetes, Obesity, Metabolism: Submitted for publication
More informationA Review of Pramlintide in the Management of Diabetes
REVIEW A Review of in the Management of Diabetes Caroline Messer and Dina Green Department of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, New York 129, U.S.A. Abstract:
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationIn the United States, most patients with type 2 diabetes fail to
n reports n Improving Treatment Success Rates for Type 2 Diabetes: Recommendations for a Changing Environment Curtis Triplitt, PharmD, CDE In the United States, most patients with type 2 diabetes fail
More informationGlucagon-like peptide-1 (GLP-1) is an
THE NEW SCIENCE OF GLP-1: EFFECTS BEYOND GLUCOSE CONTROL Richard E. Pratley, MD ABSTRACT The incretin hormone, glucagon-like peptide- 1 (GLP-1) has well-characterized effects on glucose homeostasis that
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationExecutive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23
IQWiG Reports - Commission No. A05-23 Evaluation of the therapeutic benefits and harms of exenatide 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des therapeutischen
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important
More informationResults of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 June 13, 2005 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-5203-8105 Results of Phase II Studies of Sitagliptin (MK-0431
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More information